Three cachexia phenotypes and the impact of fat‐only loss on survival in FOLFIRINOX therapy for pancreatic cancer

BACKGROUND: By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC undergoing 5‐fluorouracil, leucovorin, irinotecan, and ox...

Descripción completa

Detalles Bibliográficos
Autores principales: Kays, Joshua K., Shahda, Safi, Stanley, Melissa, Bell, Teresa M., O'Neill, Bert H., Kohli, Marc D., Couch, Marion E., Koniaris, Leonidas G., Zimmers, Teresa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104116/
https://www.ncbi.nlm.nih.gov/pubmed/29978562
http://dx.doi.org/10.1002/jcsm.12307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104116/
https://www.ncbi.nlm.nih.gov/pubmed/29978562
http://dx.doi.org/10.1002/jcsm.12307

Ejemplares similares